- Previous Close
10.75 - Open
10.75 - Bid --
- Ask --
- Day's Range
10.65 - 10.80 - 52 Week Range
10.60 - 17.25 - Volume
397,505 - Avg. Volume
952,867 - Market Cap (intraday)
7.717B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
-- - EPS (TTM)
-0.05 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.
www.taigenbiotech.com.twRecent News: 4157.TWO
View MorePerformance Overview: 4157.TWO
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4157.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4157.TWO
View MoreValuation Measures
Market Cap
7.72B
Enterprise Value
6.76B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
51.20
Price/Book (mrq)
7.13
Enterprise Value/Revenue
44.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-25.61%
Return on Assets (ttm)
-6.35%
Return on Equity (ttm)
-3.51%
Revenue (ttm)
150.65M
Net Income Avi to Common (ttm)
-38.58M
Diluted EPS (ttm)
-0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02B
Total Debt/Equity (mrq)
5.43%
Levered Free Cash Flow (ttm)
-18.62M